sabato, 8 agosto 2026

Notizie AIOM – anno XVI n. 678

ASCO 2018: Top Oncologists Select Key, Practice-Changing Abstracts

May 30, 2018 - The oncology community will soon be seeing the much-anticipated data being presented at the 2018 ASCO Annual Meeting. More than 5000 submitted abstracts will showcase findings across tumor types, which include practice-changing research in screening, immunotherapy, ...
Leggi tutto

FDA Grants Crizotinib Breakthrough Designation for MET+ NSCLC and ALK+ ALCL

May 29, 2018 - The FDA has granted crizotinib a breakthrough therapy designation for the treatment of patients with metastatic non–small cell lung cancer (NSCLC) with MET exon 14 alterations who progress after receiving platinum-based chemotherapy. The agency also ...
Leggi tutto

FDA Accepts Cabozantinib Application for Advanced HCC

May 30, 2018 - The FDA has accepted a supplemental new drug application (sNDA) for cabozantinib as a treatment for patients with previously-treated advanced hepatocellular carcinoma (HCC), according to a statement from the company developing the therapy, Exelixis. The application ...
Leggi tutto

Ulipristal acetate: new measures to minimise risk of rare but serious liver injury

June 1, 2018 - The European Medicines Agency (EMA) has recommended that several measures be put in place to minimise the risk of rare but serious liver injury with Ulipristal acetate. Certain women may start treatment with Ulipristal acetate once the new measures are implemented. ...
Leggi tutto

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 28-31 May 2018

June 1, 2018 - The European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended nine medicines for approval, including two orphan medicines1, at its May 2018 meeting. The CHMP recommended granting a marketing authorisation for ...
Leggi tutto

EMA restricts use of Pembrolizumab and Atezolizumab in bladder cancer

June 1, 2018 - Early data from two clinical trials1 show reduced survival with Pembrolizumab and Atezolizumab when used as first-line treatments for urothelial cancer (cancer of the bladder and urinary tract) in patients with low levels of a protein called PD-L1. The data ...
Leggi tutto

1 giugno 2018 – Emendamenti al modulo di consenso informato inerenti informativa e manifestazione del consenso al trattamento dei dati personali

Two more EU Member States benefit from EU-US mutual recognition agreement for inspections

June 1, 2018 - The mutual recognition agreement between the European Union (EU) and the United States (US) to recognise inspections of manufacturing sites for human medicines conducted in their respective territories has made further progress. The US Food and Drug AdministrationExternal ...
Leggi tutto

Return to work in European Cancer survivors: a systematic review

Return to work (RTW) of cancer survivors (CSs) fluctuates in different contexts. This systematic review searched for recent data on the RTW rate of CSs in Europe, investigating associated factors. Bibliographic search covered the period from January 2010 to February 2018, ...
Leggi tutto

American Cancer Society Updates Colorectal Cancer Screening Guideline

May 30, 2018 - An updated American Cancer Society guideline now says colorectal cancer screening should begin at age 45 for people at average risk, based in part on data showing rates of colorectal cancer are increasing in young and middle-aged populations. The updated recommendations ...
Leggi tutto